HC Wainwright Issues Pessimistic Estimate for DRUG Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Investment analysts at HC Wainwright dropped their Q3 2025 earnings per share (EPS) estimates for Bright Minds Biosciences in a research note issued to investors on Wednesday, February 19th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.73) for the quarter, down from their prior estimate of ($0.72). HC Wainwright currently has a “Buy” rating and a $85.00 price objective on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Bright Minds Biosciences’ Q4 2025 earnings at ($0.88) EPS, FY2025 earnings at ($2.30) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.54) EPS, Q4 2026 earnings at ($1.79) EPS, FY2026 earnings at ($5.63) EPS, FY2027 earnings at ($5.72) EPS, FY2028 earnings at ($5.80) EPS and FY2029 earnings at ($1.70) EPS.

Bright Minds Biosciences (NASDAQ:DRUG) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.24.

Other equities research analysts have also recently issued research reports about the company. Robert W. Baird began coverage on Bright Minds Biosciences in a research note on Monday, November 25th. They issued an “outperform” rating and a $75.00 target price on the stock. Piper Sandler began coverage on Bright Minds Biosciences in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $93.00 target price on the stock. Cantor Fitzgerald began coverage on Bright Minds Biosciences in a research report on Friday, January 10th. They set an “overweight” rating on the stock. Finally, Baird R W raised Bright Minds Biosciences to a “strong-buy” rating in a research report on Monday, November 25th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $84.33.

Bright Minds Biosciences Trading Down 3.3 %

NASDAQ:DRUG opened at $36.15 on Friday. Bright Minds Biosciences has a fifty-two week low of $0.93 and a fifty-two week high of $79.02. The business’s 50-day simple moving average is $38.08 and its 200-day simple moving average is $26.24.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE acquired a new position in Bright Minds Biosciences in the 4th quarter valued at $173,000. Jane Street Group LLC bought a new stake in shares of Bright Minds Biosciences during the 4th quarter valued at $238,000. Atika Capital Management LLC bought a new stake in shares of Bright Minds Biosciences during the 4th quarter valued at $540,000. Millennium Management LLC bought a new stake in shares of Bright Minds Biosciences during the 4th quarter valued at $1,454,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of Bright Minds Biosciences during the 4th quarter valued at $1,606,000. 40.52% of the stock is owned by institutional investors and hedge funds.

About Bright Minds Biosciences

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.